Healthline9d
All About Keytruda
Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...
Citius Pharmaceuticals’ Lymphir and Keytruda Combo Shows Promising Clinical Outcomes, Earning a Buy Rating
Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...
pharmaphorum2y
Keytruda encroaches on Jemperli's endometrial cancer territory
Merck & Co's KEYNOTE-158 trial of Keytruda has underpinned another FDA approval, this time for the PD-1 inhibitor as a single-agent therapy as a therapy for endometrial cancer with certain genetic ...
Cure Today7d
Keytruda Has Long-Term Survivorship Implications in Early Triple-Negative Breast Cancer
Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...
Merck posts late-stage trial win for Keytruda in head and neck cancer
Merck (NYSE:MRK) announced Tuesday that its Phase 3 KEYNOTE-689, designed to evaluate its anti-PD-1 therapy Keytruda as a ...
Investor's Business Daily on MSN2mon
Merck Dives After Summit — Up 56% — Sneaks In With Keytruda-Walloping Punch
Merck stock tumbled Monday after Summit Therapeutics' cancer drug outperformed blockbuster Keytruda in a study of lung cancer ...
7 Dividend Stocks to Buy and Hold Forever
Here are seven attractively valued dividend stocks that investors can bet on for the long term, according to Argus analysts: ...
Medicenna Reports Promising Results with MDNA11
Medicenna Therapeutics Corp (TSE:MDNA) has released an update. Medicenna Therapeutics Corp. has reported promising results from its Phase 1/2 ...
pharmaphorum3y
ESMO21: Libtayo extends survival in first-line NSCLC, challenging Keytruda
That's less impressive than the 50% reduction in death in Merck's KEYNOTE-189 trial of Keytruda in non-squamous NSCLC – which was behind its approval for first-line NSCLC alongside chemo in 2018 ...
Nasdaq20d
Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers
KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...
Cure Today1mon
Keytruda Regimen May Improve Event-Free Survival in Head and Neck Squamous Cell Carcinoma
KEYNOTE-689 trial showed significant improvement in event-free survival for stage 3 or 4A resected head and neck squamous cell carcinoma with Keytruda. Keytruda regimen included neoadjuvant therapy, ...
Barron's5mon
Competitor to Merck's Keytruda Worries Some Investors
Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab ...